IPO registrations (S-1, F-1) · Registrants

GERON CORP

SEC CIK
886744 · filings on EDGAR ↗
Name on the registration
GERON CORPORATION
Former names
GERON CORPORATION (1996–2005)
Registration
Form S-1, first filed 1996-06-12, last 1996-07-30; 1 initial registration, 4 amendments
Outcome
Final prospectus filed 1996-07-31
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
919 EAST HILLSDALE BOULEVARD, SUITE 250, Foster City, CA 94404
EIN
75-2287752
Ticker
GERN (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
GERON CORP on the corporate pages

Offering terms

Proposed price range
$8.00–$10.00 per share (S-1/A filed 1996-07-30)
Final price
$8.00 per share, within the range (424B4 filed 1996-07-31, an initial public offering)
Shares sold
2,000,000
Gross proceeds
$16,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol GERN
Lead underwriters
J.P. Morgan; Montgomery Securities (480,000 shares); Citigroup (480,000 shares)
Syndicate
Alex. Brown & Sons (100,000); Lehman Brothers (100,000); Morgan Stanley (100,000); Punk, Ziegel & Knoell, L.P (100,000)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 6

FiledFormWhat it isName as filedEDGAR
1996-06-12S-1S-1 (registration)GERON CORPORATION0000891618-96-000869 ↗
1996-06-26S-1/AS-1/A (amendment)GERON CORPORATION0000891618-96-001019 ↗
1996-07-18S-1/AS-1/A (amendment)GERON CORPORATION0000891618-96-001256 ↗
1996-07-26S-1/AS-1/A (amendment)GERON CORPORATION0000891618-96-001344 ↗
1996-07-30S-1/AS-1/A (amendment)GERON CORPORATION0000891618-96-001429 ↗
1996-07-31424B4424B4 (final prospectus)GERON CORPORATION0000891618-96-001452 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
1996-07-30S-1/Aregistration statement$8.00–$10.002,500,000-Nasdaq GERN7from the submission text; range, shares headline, cover names 7document ↗
1996-07-31424B4final prospectus$8.002,000,000$16,000,000Nasdaq GERN7from the submission text; price sentence, shares headline, proceeds computed, underwriting table 6, cover names 3document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
BEHRS MELISSA KELLYDirector,Officer; OfficerEVP BD and Port&Alliance Mgmt; EVP BD, Port & Alliance Mgmt; EVP, BD, Port & Alliance Mgmt; EVP Chief Business Officer; EVP, Chief Business Officer; EVP Portfolio & Alliance Mgmt; SVP Alliance and Prog Mgmt; SVP Oncology; SVP Portfolio & Alliance Mgmt; SVP Strategic Portfolio Mgmt; VP, Oncology382006–2021
EARP DAVIDOfficerChief Legal Counsel; SVP Bus Dev / Chf Patent Couns; SVP Bus Dev, Chief Patnt Couns; SVP, Chief Legal Officer; SVP, Corp Transactions182006–2012
GREENWOOD DAVIDDirector,Officer; Officer; OtherEVP and CFO; Executive VP and CFO; President, Interim CEO, CFO222006–2012
HARLEY CALVINOfficerChief Scientific Officer; VP and CSO; VP, CSO Telomerase Tech122006–2009
LEBKOWSKI JANEOfficer; OtherSVP, Chief Scientific Officer; SVP, CSO Regen Med; SVP, Regenerative Medicine; SVP Regen Medicine172006–2012
OKARMA THOMASDirector,Officer; OfficerPresident and CEO142006–2010
BARKAS ALEXANDER EDirector112006–2011
FRITZKY EDWARD VDirector142006–2013
HOMCY CHARLES JDirector82006–2011
KILEY THOMASDirector142006–2013
WALKER JOHN PETERDirector52006–2009
ZENNER PATRICK JDirector72006–2010
Colowick AlanOfficerPresident, Oncology62006–2008
Benedetti Fabio MOfficerSVP, Chief Med Off, Oncology52008–2009
Spink Katharine E.Officer; OtherSVP Alliance Mgmt & Operations; SVP Prgm Mgmt, Cell Therapies; VP Operations, Regen Med Progs; VP Ops, Regen Med Programs112009–2012
EASTHAM KARINDirector242009–2023
Kelsey Stephen MichaelOfficerEVP, CMO, Oncology; EVP, R&D, Chief Med Officer; EVP, R&D Head, CMO152009–2013
Hofstaetter ThomasDirector132010–2015
Huh HoyoungDirector; Director,OfficerExecutive Chairman222010–2018
Spiegel Robert J.Director712010–2026
Bloom Olivia KyusukOfficerController, Chief Acctg Off; EVP, Chief Financial Officer; SVP, CFO and Treasurer; SVP, Chief Financial Officer; VP, Chief Acctg Officer262010–2023
Nallicheri Melanie IOfficerSVP Corp Dev32011–2012
SCARLETT JOHN ADirector,OfficerChairman, President and CEO; CHAIRMAN, PRESIDENT AND CEO; Chief Executive Officer; President and CEO; President, CEO and Chairman232011–2025
ROSENFIELD STEPHENOfficerEVP, Chief Legal Officer; EVP, Chief Legal Off & Sec; EVP, Genl Counsel & Secretary; Secretary152011–2022
COOPER GRAHAM KOfficerEVP, Bus Dev & CFO32012
LAWLIS V BRYANDirector182012–2025
GRETHLEIN ANDREW JOfficerEVP, Chief Operating Officer; EVP, CHIEF OPERATING OFFICER; EVP, Development &Tech Ops; EVP, Technical Operations; EVP, Tech Ops and Development192012–2025
BRADBURY DANIELDirector162012–2019
Molineaux SusanDirector422012–2026
Parker Craig COfficerEVP, Corp Dev & Sci Affairs; SVP, Corporate Development32012–2014
Rizo AleksandraOfficerEVP, Chief Medical Officer52019–2022
Bir Dawn CarterDirector; Director,OfficerInterim President and CEO102019–2026
O'Farrell Elizabeth G.Director132019–2026
Kapur AnilOfficerEVP, Corp Strategy & CCO; EVP, CORP STRATEGY & CCO112019–2024
Feller FayeOfficerEVP, Chief Medical Officer; EVP, CHIEF MEDICAL OFFICER72022–2024
McDonald John FDirector62022–2026
Samuels Scott AlanOfficerEVP, Chief Legal Officer; EVP & CHIEF LEGAL OFFICER72023–2025
ROBERTSON MICHELLEOfficerEVP, Chief Financial Officer; EVP, CHIEF FINANCIAL OFFICER62023–2026
Aggarwal GauravDirector52023–2025
Ziegler JamesOfficerEVP, Chief Commercial Officer42024–2025
Eid JosephOfficerEVP, R&D; Chief Medical Office; EVP, Research and Development32024–2026
Semerjian HaroutDirector,OfficerPresident and CEO22025
ElNawawi AhmedOfficerEVP, Chief Commercial Officer22025
Andrews Patricia SDirector22026
Chinoporos ConstantineDirector22026
Williams TimothyOfficerEVP and Chief Legal Officer22026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Plan sponsorGERON CORPORATIONCAForm 5500 (employee benefit plans)EIN (EXACT)
SEC filerGERON CORPSEC filers (EDGAR)CIK (EXACT)
Business registrationFLORIDA GERON CORPORATIONState business registriesEIN (EXACT, as the state registration reports it)
Business registrationGeron CorporationState business registriesname and state
Business registrationGeron CorporationState business registriesname and state
Business registrationGeron CorporationState business registriesname and state
Business registrationGeron CorporationState business registriesname and state
Business registrationGERON CORPORATIONState business registriesname and state
Business registrationGERON CORPORATIONState business registriesname and state
Business registrationGERON CORPORATIONState business registriesname and state
Business registrationGERON CORPORATIONState business registriesname and state
Form 5500 plan sponsorGERON CORPORATIONEIN (EXACT)
Federal award recipientGERON CORPFederal spending (USAspending)name and state
Lobbying clientGERON CORPFederal lobbying (LDA)name and state

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.